Clinical trials: Locally Advanced Rectal Carcinoma
Rectal Cancer
FOLFOX6 Totally Neoadjuvant Chemoradiation Therapy in Locally Advanced Rectal Cancer: A Real World Study
Preoperative 5FU based chemoradiotherapy is still the standard of treatment for locally advanced rectal cancer. About 15-20% of patients would achieve pathologic complete response (pCR) after neoadjuvant CRT, and the survival…
- Trial name
- FOTAC (NCT02887313)
- Testing
- mFOLFOX6, Radiotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Rectal Cancer
Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial
Seamless phase I/II trial with phase I part for determination of maximum tolerated dose (MTD) of Trifluridine/tipiracil, followed by a randomized phase II trial (randomization ratio 2:1) with an experimental arm with…
- Trial name
- NCT04177602
- Testing
- Trifluridine/tipiracil chemoradiation, Capecitabine based chemoradiation
- Where
- 8 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Adenocarcinoma of the Rectum, Stage II Rectal Cancer
Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer
- Trial name
- NCT00006094
- Testing
- oxaliplatin, fluorouracil, external beam radiation therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer
Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer
The aims of the trial are (1) to determine the tolerability rate in the setting of a multi-centre study and (2) to determine secondary tolerability endpoints, toxicity rates and complete pathologic response rate in patients with…
- Trial name
- PROArCT (NCT01013805)
- Testing
- External Beam Radiotherapy, Oxaliplatin, Fluorouracil
- Where
- Australia
- Volunteers
- 41 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Rectal Cancer
Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer
The goal of this clinical research study is to find the highest tolerable dose of bevacizumab (Avastin) and erlotinib hydrochloride (Tarceva) that can be given in combination with standard radiation therapy and capecitabine…
- Trial name
- NCT00543842
- Testing
- Bevacizumab, Capecitabine, Erlotinib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
Previously, preliminary results, from a subgroup analysis of STARS-RC03 (NCT04906044) conducted by our research team, showed that the 6-cycles consolidation chemotherapy combining with anti-PD-1 therapy had a better tumor…
- Conditions
- Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1
- Trial name
- NCT05998122
- Testing
- nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W
- Where
- China
- Volunteers
- 45 people
- Sponsor
- The First Hospital of Jilin University
Rectal Neoplasms
Genetic Profile on Predicting Sensibility of Preoperative Chemoradiotherapy on Locally Advanced Rectal Carcinoma
The aim of this study is to find some genetic factors in predicting the sensibility of preoperative chemoradiotherapy for locally advanced rectal carcinoma.
- Trial name
- NCT01930942
- Testing
- preoperative concurrent chemoradiation
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Chinese Academy of Medical Sciences
Rectal Cancer
Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer
This study is a multicenter, open, and phase I dose increasing clinical study. Based on the UGT1A1 * 28 and * 6 genotypes of patients with locally advanced rectal cancer, determine the dose limiting toxicity (DLT) and maximum…
- Trial name
- NCT06300489
- Testing
- irinotecan liposomes+capecitabine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Locally Advanced Rectal Cancer
Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29
The aim of the ShorTrip trail is to evaluate the activity and the safety of total neoadjuvant strategy with FOLFOXIRI as consolidation therapy preceded by short-course radiotherapy and followed by surgery in LARC patients.
- Trial name
- ShorTrip (NCT05253846)
- Testing
- Irinotecan, Oxaliplatin, Lederfolin
- Where
- Italy
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Gruppo Oncologico del Nord-Ovest